Why PULMICORT RESPULES

PULMICORT RESPULES is the only branded ICS* approved for children younger than 4 years of age^1,23

NHLBI/NAEPP^† 2007 asthma guidelines recommend ICSs as the preferred first-line long-term controller therapy for mild, moderate, or severe persistent asthma.¹

PULMICORT RESPULES — for first-line treatment of persistent pediatric asthma, regardless of severity.^1,23

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.²³

In this section

Reduces Asthma Symptoms
PULMICORT RESPULES significantly reduces both nighttime and daytime symptoms.

Reduces Rescue ß₂-Agonist Use
PULMICORT RESPULES significantly reduces rescue medication use.

How PULMICORT RESPULES Works
See how PULMICORT RESPULES targets an underlying cause of asthma.

Footnotes

*Inhaled corticosteroid
^†National Heart, Lung, and Blood Institute/National Asthma Education and Prevention Program

Enlarge Text:

Print:

Educational resources for families in your care.

Links to learn about other asthma treatment options for patients:

Indication

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Important Safety Information

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Please see accompanying full Prescribing Information (PDF).

Site Map | References | Contact Us